Abstract:Voltage-gated Na+ (Nav) channels provide the basis for neuronal excitability in the brain. Of the nine Nav channel isoforms (Nav1.1-Nav1.9), Nav1.1 exhibits cell-specific distribution in fast-spiking parvalbumin (PV) interneurons in the cortical circuit. Reduced function of PV interneurons results in impairment of the cognitive domain, a bio-signature common to a variety of neuropsychiatric disorders. Thus, selective allosteric modulators targeting Nav1.1 might provide new means to rescue PV interneuron function and improve cognition. Previous studies have identified fibroblast growth factor 14 (FGF14) as a functionally relevant regulator of Nav1.1 channels. Binding of FGF14 to the Nav1.1 C-terminal tail results in modulation of Nav1.1-mediated peak transient currents and biophysical properties of the channel activation and steady-state inactivation. The FGF14:Nav1.1 protein:protein interaction (PPI) interface might therefore provide a novel target for the development of Nav1.1 allosteric modulators. In search of small molecules targeting Nav1.1, we conducted a ligand-based high-throughput virtual screening using a FGF14:Nav1.1 homology model based on available crystal structures of homologous proteins. The UCSF chimera software was used to determine the region of interaction between FGF14 and Nav1.1, and Autodock was used to create a grid box surrounding this area to identify critical amino acids at the PPI surface of FGF14.This region of interest was submitted to the Texas Advanced Computing Center (TACC) drug discovery database, which identified 1001 ZINC compounds out of 642,759 possible ligands against the interaction site. Scores ranged from −13 to 0, with lower scores indicating greater likelihood of binding to the FGF14 surface, and thus interfering with Nav 1.1 binding. On-going counter and orthogonal screenings using in heterologous systems as well as Schrödinger Advanced Drug Discovery Suite are being used to provide in-cell validation of 14 identified hits and understanding of the target-ligand interactions. These small molecules might represent a new class of PPI-based Nav1.1-specific allosteric modulators with applicability as cognitive enhancers.

In-silico design of novel myocilin inhibitors for glaucoma therapy

In Silico Screening and In Vivo Evaluation of Potential CACNA2D1 Antagonists as Intraocular Pressure-Reducing Agents in Glaucoma Therapy

Chemo-informatics guided study of natural inhibitors targeting rho GTPase: a lead for treatment of glaucoma

Exploring New Therapeutic Avenues for Ophthalmic Disorders: Glaucoma-Related Molecular Docking Evaluation and Bibliometric Analysis for Improved Management of Ocular Diseases

Identification of Novel Tyrosinase Inhibitors with Nanomolar Potency Using Virtual Screening Approaches

GCDB: a glaucomatous chemogenomics database for in silico drug discovery

Computational Study On Natural Compounds Inhibitor Of C-Myc

In Silico Screening-Based Discovery of Novel Inhibitors of Human Cyclic GMP-AMP Synthase: A Cross-Validation Study of Molecular Docking and Experimental Testing.

Histamine H3 receptor antagonist/nitric oxide donors as novel promising therapeutic hybrid-tools for glaucoma and retinal neuroprotection

In Silico Exploration of Novel EGFR Kinase Mutant-Selective Inhibitors Using a Hybrid Computational Approach

Exploration of Novel Non-Purine Xanthine Oxidase Inhibitors Based on Oxadiazolones by an Integrated Simulation Study

Biologically Driven In Vivo Occlusion Design Provides a Reliable Experimental Glaucoma Model

In Silico Exploration of Molecular Mechanisms for Inhibiting Inflammatory Responses by 3Н-Thiazolo[4,5-b]pyridin-2-one Derivatives

Integrated in Silico Fragment-Based Drug Design: Case Study with Allosteric Modulators on Metabotropic Glutamate Receptor 5

Identification of Novel Inhibitors Targeting SGK1 via Ensemble-Based Virtual Screening Method, Biological Evaluation and Molecular Dynamics Simulation

Virtual Screening in Search of Allosteric Modulators of Nav1.1 Channels

Endogenous dual stimuli-activated NO generation in the conventional outflow pathway for precision glaucoma therapy.

Computational fragment-based drug design of potential Glo-I inhibitors

Discovery of Novel Inhibitors Targeting the Macrophage Migration Inhibitory Factor Via Structure-Based Virtual Screening and Bioassays.

In silico design novel (5-imidazol-2-yl-4-phenylpyrimidin-2-yl)[2-(2-pyridylamino)ethyl]amine derivatives as inhibitors for glycogen synthase kinase 3 based on 3D-QSAR, molecular docking and molecular dynamics simulation

Quantitative structure activity relationship and molecular simulations for the exploration of natural potent VEGFR-2 inhibitors: an in silico anti-angiogenic study